# A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Source: https://onco.cc/trials/nct06190951/  
OnCo record `nct06190951` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cemiplimab, Fianlimab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma is a phase 2 interventional study registered as NCT06190951 by Regeneron Pharmaceuticals, with 151 participants enrolled, started 2024-09-18 and due to reach its primary completion in 2026-11-02. Interventions recorded: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06190951
- Phase: 2
- Setting: A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 151

## Sources

- ClinicalTrials.gov NCT06190951: https://clinicaltrials.gov/study/NCT06190951

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fianlimab](https://onco.cc/drugs/fianlimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct06190951.json